What we do Kimia Biosciences Limited is an Indian pharmaceutical company specializing in manufacturing active pharmaceutical ingredients (APIs) at its Gurgaon plant, catering mainly to domestic and international markets. |
Founded in 1,993 |
Market share Strong presence in India's bulk drug API manufacturing sector, with growing exports representing about 18% revenue share. |
Problem solved Provides quality APIs to pharmaceutical companies, addressing supply chain needs for generic and specialty drugs domestically and abroad. |
Top clients or who we serve Serves pharmaceutical formulators and manufacturers in India and export markets; operates primarily B2B. |
Key management Sameer Goel (Chairman & Managing Director), Vipul Goel (Director), Jagdeep Dhawan (Independent Director), Richa Gupta (Independent Director). |
Our journey and innovations Incorporated in 1993, renamed in 2019, expanded API manufacturing, improved GMP compliance, and developed in-house raw material processes. |
Where we operate Primarily India with export markets contributing about 18% of revenue. |
Top products or what we offer Manufactures bulk drugs including Brivaracetam, Dapagliflozin, Delafloxacin, Rivaroxaban, Apixaban, and vitamin B1 derivatives. |
Top brands No consumer brands; key APIs include Brivaracetam, Dapagliflozin, Delafloxacin, Rivaroxaban, Apixaban with robust GMP certifications. |
Raw materials needed Chemical intermediates and raw chemicals for API synthesis; some raw materials manufactured in-house. |
Raw materials supplier Not explicitly detailed; company develops key raw material intermediates internally to reduce dependence. |
Recurring vs cyclical contribution Revenues primarily recurring from long-term contracts with pharmaceutical manufacturers; supported by steady demand. |
Our industry position Stable player with capacity utilization above 90%, recognized ancillary unit supporting major pharmaceutical companies. |
Financial highlights FY 2024-25 revenue of Rs. 118.92 cr and net profit of Rs. 9.61 cr, showing strong operational recovery and profitability growth. |
Geographical revenue split Approximately 82% revenue from India and 18% from exports. |
Order book - |
Whats driving growth Increased pharmaceutical demand, successful capacity utilization, robust marketing, enhanced GMP compliance, and cost-efficient manufacturing. |
Our future plans Focus on product R&D, plant upgrades, enhancing technology absorption, and expanding export footprint. |
Our green promise Committed to energy conservation with upgrades in equipment and processes to minimize environmental impact. |
Our people and values Maintains ethical workforce with focus on safety, diversity, and continuous employee development. |
Key challenges ahead Raw material price volatility, regulatory compliance, competition, and global market fluctuations. |
Interesting facts One of India's precursor pharmaceutical companies to adopt extensive energy conservation initiatives and in-house raw material development. |
Risks and strategy Mitigates risks through diversified products, strict regulatory adherence, internal controls, and innovation-driven growth. |
